| Literature DB >> 22902149 |
Inga Hoffmann1, Martin Roatsch, Martin L Schmitt, Luca Carlino, Martin Pippel, Wolfgang Sippl, Manfred Jung.
Abstract
Reversible histone methylation has emerged in the last few years as an important mechanism of epigenetic regulation. Histone methyltransferases and demethylases have been identified as contributing factors in the development of several diseases, especially cancer. Therefore, they have been postulated to be new drug targets with high therapeutic potential. Here, we review histone demethylases with a special focus on their potential role in oncology drug discovery. We present an overview over the different classes of enzymes, their biochemistry, selected data on their role in physiology and already available inhibitors.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22902149 PMCID: PMC5528348 DOI: 10.1016/j.molonc.2012.07.004
Source DB: PubMed Journal: Mol Oncol ISSN: 1574-7891 Impact factor: 6.603